Opko Health (OPK) Q3 2026 earnings review
Opko Health sells its testing labs while drug sales rise
Opko Health, a maker of specialty medicines and operator of clinical testing labs, is exiting the lab business entirely to become a drug developer. The company agreed to sell its remaining BioReference testing labs to Labcorp for $722 million in cash at closing plus up to $150 million in future milestones. In the remaining drug business, third-quarter sales rose 16% to $65 million as diabetes drug royalties from Eli Lilly turned the commercial medicine division profitable.
| Labcorp buyout of remaining testing labs | $722M cash plus up to $150M in 4Kscore milestones |
|---|---|
| Continuing biopharma revenue | $65.4M +16% from a year ago |
| Global Products segment operating result | $6.0M profit $1.2M loss a year ago |
| Full-year IP and royalty revenue outlook | Raised $5M middle of the range: $107.5M |
⚖️ Verdict: 🟢 Bullish
The story got better because the Labcorp sale removes a money-losing testing division that missed its own breakeven targets and brings in more cash than the company's entire debt load. One caution: the testing unit missed its third-quarter sales plan before the exit, and the company borrowed $125 million against future Eli Lilly royalties, pushing debt up to $463 million by our math.
The question now is how much net cash Opko Health keeps after the lab sale closes and how fast its cancer and hormone drug trials burn through it. Either the $722 million payout closes near full value and funds the pipeline for years, or shrinking lab sales trigger closing price cuts while quarterly losses near $36 million drain the cash pile. The final closing statement with Labcorp and early 2027 clinical trial readouts will tell.
🐂 Bull Case
Labcorp Deal Brings Up to $872 Million
Opko Health, a maker of specialty medicines and operator of clinical testing labs, spent the past year trying to fix its money-losing BioReference testing division. After selling the cancer testing unit to Labcorp in late 2025, the company agreed this quarter with Labcorp "for the sale of substantially all remaining BioReference diagnostic operations".
The deal brings $722 million in cash at closing, adjusted for final sales levels, plus up to $150 million over ten years tied to sales of 4Kscore, a blood test for prostate cancer risk. Exiting the lab business removes a persistent cash drain and leaves more than enough cash to pay off all $462.7 million of debt while funding drug trials for years.
What to watch: regulatory approval and the final closing revenue adjustment for the Labcorp sale. Closing without a large downward price adjustment will lock in the cash windfall and complete the exit from medical testing.
Commercial Drugs and Royalties Turned Profitable
Global Products, the division housing commercial medicines and international distribution, moved from a $1.2 million operating loss a year ago to a $6.0 million operating profit this quarter. Across all continuing operations, the operating margin improved by 11.6 percentage points as cost of revenue (the direct cost of making products) fell by 2.3 percentage points of sales and overhead fell by 1.6 points.
- Global Products revenue: $48.4 million, up 22.8% from a year ago
- Eli Lilly royalty on mazdutide (a diabetes and weight-loss drug sold in China): $5.8 million
- Rayaldee (a vitamin D pill for kidney disease): $8.6 million, up 14.7% from a year ago
- International operations: $33.2 million, up 9.9% from a year ago
Rayaldee sales rose because of "favorable gross-to-net adjustments as a result of changes to our Medicare Coverage", meaning the drugmaker kept more money per prescription after rebates. A profitable commercial drug division lowers the cash burn of the remaining company.
What to watch: fourth-quarter licensing and royalty revenue against the $21 million to $27 million outlook. Hitting the top half of that range will show that Eli Lilly royalties can keep the commercial segment profitable every quarter.
Clinical Pipeline Expanded With First Acromegaly Dosing
With the testing labs leaving, the long-term case rests on Innovative Biotech, the research unit developing experimental antibodies and long-acting proteins. The biopharma group dosed the first participant in an early-stage human trial of OPK-8801001, a once-weekly injection for acromegaly (a hormone disorder that causes excess growth), and finished enrolling its government-funded COVID-19 antibody study.
Meanwhile, three cancer antibody trials at its ModeX unit and a study of OPK-88006, an injectable drug for liver disease and obesity, continued enrolling patients on schedule. Research spending in the biotech segment rose 15.6% to $30.4 million due to "increased investment in ModeX development programs".
What to watch: early human data from the MDX2301 COVID-19 trial due in late 2026 or early 2027, followed by safety and immune results for cancer drugs MDX2001 and MDX2004 in the first half of 2027. Positive safety and immune activity will test whether the antibody platform works in patients.
🐻 Bear Case
Testing Lab Missed Targets Before the Exit
In earlier quarters, executives repeatedly stated that the BioReference testing business was on track to break even by the middle of 2026 and deliver profitable growth in the second half. Instead, the lab unit missed its third-quarter sales target and stayed deep in the red right as the board agreed to sell it.
- BioReference Q3 sales: $71.8 million, below the $73 million to $78 million plan
- Sales from lab operations owned a year ago: down 5.2% by our math, after stripping out $19.5 million of sold cancer-testing revenue from the year-ago quarter
- BioReference Q3 operating loss: $18.8 million
- Planned Q4 loss from discontinued operations: $35 million to $45 million
This matters for two reasons. First, Opko Health still absorbs the lab unit's losses until the sale closes, and the fourth-quarter plan points to a much wider loss. Second, the $722 million sale price is subject to adjustments based on closing revenue, so shrinking lab sales could reduce the final cash payout.
What to watch: discontinued operations revenue and loss in the fourth quarter. A further drop in lab sales before closing would directly threaten the $722 million headline price from Labcorp.
Royalty Loan Mortgages Future Eli Lilly Payments
Royalties from Eli Lilly on mazdutide were the main reason the commercial drug division turned a profit this quarter. However, the Florida-based drugmaker simultaneously issued $125 million of new "senior secured royalty notes" to HealthCare Royalty, pledging specified future Eli Lilly mazdutide payments to back the loan.
The borrowing brought in $123.1 million in net cash, but it pushed total debt from convertible bonds and royalty loans up 39.6% since December to $462.7 million, by our math. Trading away future high-margin royalty cash flows for upfront debt weakens the earnings power of the remaining drug business, especially when the Labcorp sale is already set to bring in $722 million.
What to watch: interest expense and royalty debt repayment terms in the full quarterly filing. They will show how much of the Eli Lilly royalty stream HealthCare Royalty will keep each quarter.
Pfizer Profit Share Stalled in the Quarter
Opko Health receives a share of gross profits from Pfizer on sales of Ngenla, a once-weekly growth hormone injection. After jumping in the first half of the year against easy comparisons, payments from the Pfizer partnership came in at $8.7 million this quarter, down slightly from $8.8 million a year ago.
The company held its full-year target for Pfizer payments at $34 million to $37 million, which requires a jump to between $12.5 million and $15.0 million in the fourth quarter. Earlier in the year, executives noted that patients were switching from daily injections more slowly than expected, and the third quarter showed no acceleration.
What to watch: fourth-quarter Pfizer profit-share revenue against the $12.5 million to $15.0 million target. Missing that seasonal step-up would confirm that Ngenla market share gains have slowed.
Four Standing Questions Left Unanswered
The third-quarter release gave no update on four clinical and commercial milestones that executives highlighted earlier in the year.
- Epstein-Barr virus vaccine with Merck: no word on Phase 1 data analysis or whether Merck will advance the vaccine to Phase 2 in 2027.
- In vivo CAR-T cell therapy: no update on whether the gene-delivery program will enter human trials in China by late 2026 or early 2027 as targeted.
- Oral hormone pill with Entera Bio: no mention of the application to start human trials for hypoparathyroidism, previously slated for late 2026.
- Rayaldee prescription volume: the release cited Medicare rebate changes for higher sales, without stating whether underlying prescriptions are still falling near 17% to 20%.
👓 Other Themes
New Two-Segment Structure Separates Cash From R&D
Because the Labcorp agreement is "a strategic shift that will eliminate substantially all remaining diagnostic operations", the company moved BioReference into discontinued operations and recast past periods. Continuing operations are now split into Global Products, Innovative Biotech, and unallocated corporate overhead ($10.6 million loss in Q3) "to provide a clearer view of the biopharmaceutical businesses that will remain with OPKO following the planned transaction".
Currency Gains Lifted International Drug Sales
International pharmaceutical revenue grew by $3.0 million from a year ago to $33.2 million on higher volumes at its EirGen unit and stronger animal health demand. Favorable exchange rates provided a $0.7 million boost to those international sales, driven by a stronger Chilean peso and Mexican peso against the US dollar.
💲 Other KPIs
Cash, cash equivalents and restricted cash rose from $314.4 million at the end of June to $403.2 million ($390.2 million in current cash on the balance sheet). The increase came from $123.1 million in net proceeds from the new HealthCare Royalty loan and $19.8 million released from escrow on last year's cancer lab sale.
The biopharma group bought back 7.05 million shares during the quarter for $10.6 million, or about $1.50 per share by our math. That brings total spending under the $200 million buyback plan to $115.7 million since July 2025, leaving $84.3 million available for future purchases.
Accounts receivable — money owed by customers for products and services already delivered — stood at $80.2 million, down 11.2% from $90.3 million at the end of 2025 after moving the testing lab assets into held-for-sale accounts.
🔮 Guidance
Cut to remove the testing lab. After stripping out BioReference services, the full-year plan for the remaining biopharma business calls for $273 million at the middle of the range, up 15.4% from $236.6 million in 2025 by our math.
New. The fourth-quarter plan calls for $67 million at the middle of the range. By our math, that is down 13.4% from $77.4 million of pharmaceutical sales in the fourth quarter of 2025, when the drugmaker booked a $7.2 million upfront payment from Regeneron.
Cut at the top end. Management trimmed the upper bound by $5 million, lowering the middle of the range by $2.5 million to $166.5 million. Across four quarters, the middle of the full-year product outlook moved from $165 million to $169 million and now $166.5 million. The fourth-quarter product target is $41.0 million to $46.0 million.
Raised. The licensing and royalty outlook moved up $5 million after the third-quarter beat from Eli Lilly royalties. Across the last three updates, the middle of the range rose by $0 million, $27.5 million, and now $5 million. The fourth-quarter target is $21.0 million to $27.0 million.
Unchanged. The full-year target has stayed at $34 million to $37 million for four straight quarters. With $21.2 million booked through September, the fourth-quarter target of $12.5 million to $15.0 million requires a 10% rise at the middle of the range over last year's fourth-quarter record.
Raised at the bottom end. The floor moved up $2 million after third-quarter government contract revenue beat expectations at $7.5 million. The fourth-quarter target is $3.0 million to $5.0 million, down 42% at the middle of the range from $6.9 million a year ago.
Cut to remove the testing lab. The company withdrew its prior consolidated expense plan and issued a $390 million to $395 million target for continuing operations, with $100 million to $105 million planned for the fourth quarter. By our math, the fourth-quarter revenue and cost ranges point to a continuing operating loss of $35.5 million at the middle of the range.
Trimmed at the top end. The upper bound came down by $5 million after third-quarter research spending landed below the planned range. For the fourth quarter, research and development spending is planned at $32.0 million to $35.0 million.
New. With BioReference moved to discontinued operations and services revenue guidance withdrawn, the company forecast a full-year discontinued net loss of $60 million to $70 million, including a $35 million to $45 million loss in the fourth quarter.
❓ Key Questions
How could closing revenue adjustments reduce the $722 million payout?
The Labcorp purchase price is subject to adjustments based on BioReference revenue at closing. Because BioReference missed its third-quarter sales target and dropped 5.2% on a like-for-like basis, investors need the revenue floor required to receive the full $722 million.
Why borrow $125 million against Lilly royalties before closing Labcorp?
Opko Health ended June with over $314 million in cash and just agreed to sell BioReference for $722 million. Pledging future Eli Lilly mazdutide royalties for a $125 million loan encumbers a key high-margin cash stream right when cash is plentiful.
What drives the $35–45 million fourth-quarter discontinued operations loss?
BioReference lost $18.0 million net of tax in the third quarter and $25.6 million across the first nine months of 2026. The outlook for a $35 million to $45 million loss in the fourth quarter alone implies either worse operating losses or large deal charges.
Are Rayaldee prescription volumes still falling despite the Medicare benefit?
Rayaldee revenue rose 14.7% to $8.6 million on Medicare rebate changes. In late 2025, similar rebate gains masked a 17% to 20% drop in underlying prescriptions, and the release did not disclose third-quarter prescription volume.